Impact of Antidepressant Black Box Juggled By Advisory Committee, FDA
Executive Summary
The addition of new, positive data on adult suicidality to antidepressant labeling could be an opportunity to offset the negative impact the "black box" warning on pediatric suicidality has had on antidepressant use, according to members of FDA's Psychopharmacologic Drugs Advisory Committee
You may also be interested in...
FDA Faces “Daunting” Mission As It Partners With Doctors For Safe Rx Use
One of FDA's mantras has been that is does not regulate the practice of medicine, and while the agency remains committed to that doctrine, it is now trying to find ways to better influence how doctors prescribe and discuss drugs through its "Safe Use" initiative
FDA Faces “Daunting” Mission As It Partners With Doctors For Safe Rx Use
One of FDA's mantras has been that is does not regulate the practice of medicine, and while the agency remains committed to that doctrine, it is now trying to find ways to better influence how doctors prescribe and discuss drugs through its "Safe Use" initiative
FDA’s Risk Communication Efforts Include Surveying Docs On Adverse Events
FDA is seeking physicians' input as the agency reviews its efforts to communicate emerging risks in medical products